IP Library Granted Patent US 7,217,684
Granted Patent B2
US 7,217,684 · App. 10/843,759 · Granted May 15, 2007

Process and composition for cleaning medical instruments

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,217,684
App. No.
10/843,759
Granted
May 15, 2007
Kind
B2
Abstract

The invention relates to a method for cleaning a contaminated medical instrument including the step of immersing the instrument in a solution containing an enzyme based cleaning composition including a “hospital grade disinfectant”. Compositions useful for cleaning contaminated medical instruments in accordance with the method include an enzyme, a quat biocide and an “activity protector”, which may be for example, enzyme stabilizers, enzyme stabilizing systems, micelle formation modifiers and inhibitors, and combinations thereof.

Claims (29)

1. A liquid composition for reducing inoculum on a medical instrument contaminated with an organic load including a protein, said composition comprising:

a protease;

a mono quaternary ammonium biocide;

an activity protector which is a boron compound; and

a polyol having from 2 to 6 hydroxyl groups, wherein said composition is shelf-stable and provides at least 8 log reduction in inoculum density within 8 minutes on the medical instrument contaminated with an organic load including a protein.

2. A composition according to claim 1 wherein the polyol is selected from the group consisting of ethylene glycol, propylene glycol 1 ,2-propanediol, butyleneglycol, glycerol, mannitol, sorbitol, erythritol, glucose, fructose and lactose.

3. A composition according to claim 2 wherein the polyol is selected from the group consisting of glycerol, mannitol, sorbitol, erythritol, glucose, fructose and lactose.

4. A composition according to claim 1 wherein the biocidal efficacy of the quaternary biocide is protected by a micelle immiscible solvent.

5. A composition according to claim 4 wherein the micelle immiscible solvent is selected from the group consisting of C1–C6 alkanols, C1–C6 diols, C3–C24 alkylene glycol ethers, alkylene glycol alky ethers, and mixtures thereof.

6. A composition according to claim 5 wherein the solvent includes di (propylene glycol) methyl ether.

7. A composition according to claim 1 further including a non ionic surfactant.

8. A composition according to claim 1 being a shelf stable liquid disinfectant concentrate composition containing at least 1% by weight of a quaternary biocide and capable of dilution with 20 parts of water to 1 part of concentrate, the diluted solution exhibiting a Minimum Inhibitory Concentration (“MIC”) after 24 hrs in the presence of up to 2% of tryptone (or the protein equivalent thereof) which is less than the MIC of a solution of the same concentration of the same quaternary biocide in distilled water in the presence of the same amount of the protein.

9. A composition according to claim 8 wherein the protease is subtilisin.

10. A composition according to claim 8 wherein the concentrate is diluted by more than 20 parts of water to 1 part of concentrate.

11. A composition according to claim 8 wherein the concentrate is diluted by more than 100 parts of water to 1 part of concentrate.

12. A composition according to claim 8 wherein the concentrate is diluted by more than 200 parts of water to 1 part of concentrate.

13. A composition according to claim 1 wherein the mono quaternary ammonium biocide is a monomeric quaternary ammonium antimicrobial compound selected from the group having a general formula:

wherein R′, R″, R′″, R″″ are alkyl radicals that may be the same or different, substituted or unsubstituted, branched or unbranched, and cyclic or acyclic, and X is any anion.

14. A composition according to claim 13 wherein X is chlorine, bromine or other halogen.

15. A composition according to claim 1 wherein the mono quaternary biocide is selected from the group consisting of mono-long-alkyl chain, tri-short chain, tetralkyl ammonium compounds; di-long-chain, di-short chain tetralkyl ammonium compounds and mixtures thereof.

16. A composition according to claim 1 wherein the mono quaternary biocide is selected from the group consisting of monoalkyltrimethyl ammonium salts, monoalkyldimethylbenzyl compounds, dialkylbenzyl compounds and quaternary gluconates.

17. A composition according to claim 1 wherein the biocide is selected from the group consisting of C8 to C22 dimethyl benzyl ammonium chloride, C8–C22 dimethyl ethyl benzyl ammonium chloride and di- C6–C20 alkyl dimethyl ammonium chloride.

18. A composition according to claim 1 wherein the mono quaternary biocide is a benzyl dimethyl ammonium halide.

19. A composition according to claim 1 wherein the boron compound is selected from the group consisting of boric acid, boric oxide, borax, sodium ortho-, meta-, or pyro-borate or perborates.

20. A composition according to claim 1 wherein the boron compound includes sodium tetraborate.

21. A composition according to claim 1 wherein the composition further includes as an enzyme stabilizer, a compound selected from the group consisting of formates, calcium ions, polyfunctional amino compounds, phosphates, citrates, sulphates or sequestering agents.

22. A composition according to claim 1 wherein the composition further includes one or more enzymes selected from the group consisting of hydrolases, carbohydrases, esterases, hydrases, amylases, catalases, lipases, amylases, cellulases, peroxidases, invertases and mixtures thereof.

23. A composition according to claim 1 further including a micelle formation inhibitor.

24. A composition according to claim 5 further comprising a compound selected from the group consisting of borates, lactates, citrates, tartrates and mixtures thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 5, 2007
From: SAVA, ALEX; KRITZLER, STEVEN
To: NOVAPHARM RESEARCH (AUSTRALIA) PTY LTD
Reel/Frame 019519/0783 →
Priority Claims (1)
AU PQ6791 · Apr 7, 2000 · national
Continuity (2)
Continuation 1025708800
Related Publication 20040209790A1 · Oct 21, 2004